A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects
Latest Information Update: 18 Mar 2022
At a glance
- Drugs DC 371739 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou JOYO Pharma
- 15 Mar 2022 Status changed from active, no longer recruiting to completed.
- 27 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 31 Dec 2021.
- 27 Jul 2021 Status changed from recruiting to active, no longer recruiting.